Alivus Life Sciences has reported improved financial performance in its third quarter results, with net profit showing steady growth compared to the same period in the previous year. The company's bottom-line performance reflects consistent operational execution during the quarter.

Financial Performance Overview

The company's third quarter financial results demonstrate positive momentum in profitability metrics. The net profit figures indicate sustained business performance and effective cost management strategies during the reporting period.

Quarterly Results Analysis

The year-over-year comparison shows that Alivus Life Sciences achieved a net profit of ₹1.50 billion in the third quarter, representing an increase from ₹1.40 billion recorded in the corresponding quarter of the previous year. This translates to a growth rate of 7.14%, indicating steady business expansion and improved operational efficiency.

The positive financial trajectory suggests that the company has maintained its competitive position while effectively managing its operational costs. The consistent profit growth demonstrates the company's ability to generate value for its stakeholders through sustained business performance.

Business Performance Indicators

The quarterly results reflect the company's operational stability and financial discipline. The improvement in net profit margins indicates effective resource utilization and strategic business management. This performance metric serves as a key indicator of the company's overall business health and management effectiveness during the reporting quarter.

Alivus Life Sciences Limited has announced the allotment of 55,000 equity shares under its Employee Stock Option Scheme 2021. The company's Nomination and Remuneration Committee approved this allotment during its meeting held on January 21, 2026.

Share Allotment Details

The allotted shares have a face value of ₹2.00 each and were issued to eligible employees who exercised their stock options under the Employee Stock Option Scheme 2021. This allotment represents the company's commitment to its employee incentive programs and stock-based compensation structure.

Impact on Share Capital

The allotment has resulted in an increase in the company's paid-up share capital structure:

The allotment increased the total number of outstanding equity shares by 55,000, representing a marginal increase in the company's equity base. The paid-up share capital rose by ₹1,10,000, reflecting the face value of the newly allotted shares.

Regulatory Compliance

Alivus Life Sciences has informed both the BSE Limited and National Stock Exchange of India Limited about this allotment, ensuring compliance with listing requirements and transparency obligations. The company operates under scrip code 543322 and trades under the symbol ALIVUS on the stock exchanges.

Company Background

Alivus Life Sciences Limited, formerly known as Glenmark Life Sciences Limited, maintains its corporate office at Technopolis Knowledge Park in Mumbai and registered office in Solapur. The company continues to utilize employee stock option schemes as part of its talent retention and incentive strategy.